Pharming Group Nv Stock Current Liabilities
| PHARM Stock | EUR 0.83 0.02 2.35% |
Pharming Group NV fundamentals help investors to digest information that contributes to Pharming Group's financial success or failures. It also enables traders to predict the movement of Pharming Stock. The fundamental analysis module provides a way to measure Pharming Group's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pharming Group stock.
Pharming |
Pharming Group NV Company Current Liabilities Analysis
Pharming Group's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
In accordance with the recently published financial statements, Pharming Group NV has a Current Liabilities of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The current liabilities for all Netherlands stocks is 100.0% higher than that of the company.
Did you try this?
Run Bonds Directory Now
Bonds DirectoryFind actively traded corporate debentures issued by US companies |
| All Next | Launch Module |
Pharming Fundamentals
| Return On Equity | 0.17 | |||
| Return On Asset | 0.0643 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.18 % | |||
| Current Valuation | 683.14 M | |||
| Shares Outstanding | 652.41 M | |||
| Shares Owned By Insiders | 1.97 % | |||
| Shares Owned By Institutions | 16.43 % | |||
| Price To Earning | 22.31 X | |||
| Price To Book | 3.85 X | |||
| Price To Sales | 3.57 X | |||
| Revenue | 167.68 M | |||
| Gross Profit | 177.73 M | |||
| EBITDA | 41.22 M | |||
| Net Income | 16 M | |||
| Cash And Equivalents | 63.89 M | |||
| Cash Per Share | 0.10 X | |||
| Total Debt | 122.65 M | |||
| Debt To Equity | 84.60 % | |||
| Current Ratio | 1.53 X | |||
| Book Value Per Share | 0.30 X | |||
| Cash Flow From Operations | 37.84 M | |||
| Earnings Per Share | 0.04 X | |||
| Target Price | 8.02 | |||
| Number Of Employees | 277 | |||
| Beta | 0.98 | |||
| Market Capitalization | 811.08 M | |||
| Total Asset | 350.55 M | |||
| Z Score | 3.6 | |||
| Net Asset | 350.55 M |
About Pharming Group Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pharming Group NV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharming Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharming Group NV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Information and Resources on Investing in Pharming Stock
When determining whether Pharming Group NV is a strong investment it is important to analyze Pharming Group's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pharming Group's future performance. For an informed investment choice regarding Pharming Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pharming Group NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.